strategi out-grow peer
messag agil analyst day posit believ compani
consist strategi allow drive growth upper end long-term
target better new product launch align healthi end market
condit thought agil impress job highlight strength
manag bench effici overview compani invest
thesi simpli put agil end market healthi believ focus
strategi util agil enterpris strength allow outgrow peer
go increment invest near term bring new
product market clinic workflow oligo
capac view invest posit given agil healthi
track record innov recent highlight includ intuvo gc ultivo lc/m
tq compani highlight growth excess organ growth target
drive increment oper margin vs current averag capit
deploy remain signific opportun agil net cash posit
ttm ebitda point pleas agil opportunist
repurchas million share may given stock weak
earn continu believ agil premium growth deserv
premium valuat versu peer reiter overweight rate
action modestli lower forecast increment invest
expect new product ep vs previous
return equiti ttm
dear client appreci consider institut investor all-america
equiti research survey view year roster pleas click
link barclay live interact chart
quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
overweight agil built strong track
record reput oper perform
develop divers portfolio busi
across instrument diagnost favor
agil exposur growth biopharma
rev new product cycl ga chromatographi
opportun repatri drive upsid
improv growth chemic energi end
market due stabil trend gc product
cycl could lead better growth capit alloc
also remain opportun upsid case
reflect upsid ebitda billion
agil exposur econom activ end
market could impact growth downsid
case reflect downsid ebitda
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
messag agil analyst day posit believ compani
consist strategi allow drive growth upper end long-term target
better new product launch align healthi end market condit
thought agil impress job highlight strength manag
bench effici overview compani invest thesi simpli put
agil end market healthi believ focus strategi util agil
enterpris strength allow outgrow peer go
increment invest near term bring new product market clinic
workflow oligo capac view
invest posit given agil healthi track record innov recent
highlight includ intuvo gc ultivo lc/m tq compani highlight growth
excess organ growth target drive increment oper margin
vs current averag capit deploy remain signific opportun
agil net cash posit ttm ebitda point pleas
agil opportunist repurchas million share may given stock
weak earn continu believ agil premium growth
deserv premium valuat versu peer reiter overweight rate
modestli lower forecast increment invest expect new
product reiter overweight rate price target
forecast adjust ep vs previous price target repres
ebitda forecast billion price target previous base
prior ebitda forecast billion
ceo mike mcmullen consist strategi success
thought ceo mike mcmullen effect job highlight agil strength
allow compani out-grow peer group next sever
year agil premium portfolio life scienc tool diagnost technolog
compani exposur product workflow across liquid chromatographi player
ga chromatographi player anatom patholog top posit agil drive
custom success uniqu workflow addit agil global scale posit
compani well growth emerg market china compani
revenu agil transform consist ceo mcmullen year
lead compani includ streamlin organ divestitur non-
core asset keysight nmr busi mcmullen focus acceler
growth deliv oper margin expans return capit sharehold
point ceo mcmullen note compani opportunist repurchas
million share may given recent stock weak compani also close
two tuck-in acquisit aati ultra scientif young
favor compani consist strategi thought investor day messag
continu track record
ceo mcmullen talk refresh strategi agil though believ
screen consist mani thing compani alreadi agil
size address market across key end market agil team
evalu opportun compani end market geographi
think uniqu capabl win achiev success ceo
mcmullen highlight compani focu innov bolt-on digit
technolog specif opportun mcmullen highlight includ cancer diagnost
dx biopharma within pharma end market cancer research academ govern
china india food/environment grow instal base china
agil meaning success intern invest plan invest
billion next year around compani revenu
recent progress led major launch compani includ intuvo
gc ultivo tq lc/m openlab ecm futur expect major new launch
includ clinic workflow
bolt-on ceo mcmullen reiter look transform
acquisit mcmullen framework includ look market compani know well
understand go market strategi busi model technolog
oper regulatori environ ceo mcmullen use seahors bioscienc
exampl recent tuck-in work last quarter seahors
deliv revenu growth oper margin increment despit increas
 invest agil quickli achiev attract growth margin target
given abil leverag erp system share servic fulfil team expand
custom reach seamless custom interfac access agil engin
agil net debt ebitda
cfo didier hirsch lt guidanc screen conserv
believ agil long-term guidanc screen conserv context
compani attract end market condit prospect new product launch
abil drive healthi increment oper margin ampl balanc sheet
flexibl cfo didier hirsch gave overview busi model agil
detail annual project busi
cfo hirsch start oper margin compani done
effect job drive increment expans organ growth base organ
growth hirsch estim busi gener increment oper
margin vs aggreg margin around growth beyond base
growth expect pull increment margin swing
factor weigh expans fx well tuck-in
initi dilut margin lasergen clinic invest near-
term invest technolog platform lead compani set initi
oper margin rang vs current forecast
beyond compani expect oper margin expans per year
key formula above-market revenu growth agil
abl drive time agil deliv around organ growth
growth acceler chemic energi market began
show improv compani forecast long-term organ growth
screen conserv us context healthi end market
new product initi forecast upper end rang per year
growth y/i debt ebitda barclay agil
lead analyt lab
jacob thaysen new presid lsag divis agil previou presid
dgg provid detail agil strategi becom leader analyt lab
compani approach revolv around expand market share custom
centric approach except valu proposit compani serv differ end
market varieti instrument common agil end custom
scientist look similar instrument workflow attribut driven
custom demand agil focus improv lab econom advanc scientif
capabl acceler time result lead compani narrow
sever key growth initi market platform initi highlight
informat agil believ informat platform increasingli becom
central part custom vendor select thaysen highlight compani
openlab platform help agil custom drive effici ensur
regulatori complianc enabl standard workflow capabl
platform grow openlab continu invest prioriti
better manag laboratori aspect drive effici lab also
allow agil offer new product servic custom recent
acquisit genohm complet compani informat capabl ad
separ technolog agil focus improv upon leadership posit
separ technolog thaysen discuss compani intuvo ga
chromatographi gc infin seri liquid chromatographi lc instrument
intuvo gc platform launch month ago garner posit
custom feedback instrument design workflow consider mind
result platform ease-of-us industri lead agil rebrand
infin lc instrument line complet workflow solut call infinitylab sell
complet workflow custom optim method maintain high level
launch asm target billion address opportun
grow high-singl digit platform footprint smaller compar
previou triple-quad instrument allow custom maxim space effici
laboratori footprint small custom impress
power resolut instrument
cell analysi agil enter market cellular analysi acquisit
seahors bioscienc earlier present ceo mike mcmullen note
busi grown revenu last four quarter market cellular
analysi driven underli complex understand live cell
demand scientist look better tool cellular analysi expect
area organ inorgan invest futur
biopharma thaysen highlight agil opportun biolog compani
size billion grow double-digit compani strategi
revolv around provid complet workflow solut custom compani
provid assaymap bravo system front end biocolumn analysi stage
bioconfirm softwar back end agil aim bring simplic
biochemist tri use instrument workflow understand complex larg
molecul agil provid solut custom area
research manufactur
academ govern research agil believ under-penetrated
academ govern end market present market share opportun
rel lower growth segment market view support compani
product portfolio agil believ well posit target custom
part agil strategi improv compani brand recognit
custom highlight recent partnership academ
institut includ imperi colleg london univers
lastli thaysen wrap lsag discuss expand segment margin
initi agil aim simplifi compani oper use agil
scalabl process thaysen highlight opportun new product develop
commerci sell process manufactur suppli chain manag
gener tool allow collabor across divis help agil drive
advanc technolog improv cost valu engin
area commerci compani work improv quote-to-cash
process leverag price tool
mark doak agil crosslab group acg win lab
mark doak presid acg divis agil discuss compani
servic consum busi critic bring innov solut
marketplac compani improv custom valu proposit
laboratori product servic workflow solut differenti custom experi
part improv custom experi agil invest digit capabl
hope benefit broader market trend digit enabl world
laboratori continu pressur improv product play well
compani strategi innov come technolog also innov
term custom experi compani enterpris servic start
core instrument servic mainten repair agil continu layer
valu add servic consult inventori manag instrument
monitor crosslab connect outsourc continu agil see
opportun suppli custom gener less well equip compar
biopharma come market complet workflow infinitylab lc
agil see increas consum order addit agil
opportun drive growth introduc new product custom workflow
exampl acquisit ultra scientif chemic standard compani agil
plan introduc biopharma standard product workflow custom
final china expect continu double-digit grower driven demand
plan ytd acg grown china number factor repres tailwind
growth includ matur aftermarket larg instal base digitally-connect
agil encourag progress consum busi repres
compani total revenu includ sampl prep suppli column
compani work unlock potenti busi focu market
channel initi result momentum busi pick
recent growth double-digit busi also high-margin oper
margin compani averag
agil util varieti technolog improv custom experi
establish differenti custom experi major focu new
agil custom rank top compani term
custom satisfact agil aggress build e-commerce platform
grown recent year agil see signific upsid busi
doak note would surpris see on-line busi doubl
come year compani continu invest digit lab offer includ
ilabsaa openlab crosslab agil also autom number process
includ order autom order easier custom also
signific time-sav compani sale rep agil focus autom
back offic function well manufactur suppli chain
raha diagnost genom group dgg high
raha presid diagnost genom group discuss number growth
driver segment notabl high growth market clinic
nucleic acid dgg primarili serv custom cancer diagnost
biopharma end market strength patholog lab companion diagnost
major advantag agil embark new product launch clinic
area growth segment includ china repres
segment revenu well companion diagnost compani
establish player raha also identifi number initi improv margin within
dgg segment offer product e-commerce platform particularli
consum addit dgg join agil segment activ util
price disciplin final raha note increas emphasi place
integr acquisit order drive superior growth margin expans
exampl dgg recent realiz full capabl dako infrastructur
complet compani integr
raha identifi base clinic oncolog current million address
market grow annual compani believ ngss presenc
clinic set continu expand transform cancer diagnost raha note
clinic adopt benefit regulatori clariti improv payor coverag
clinic still earli stage agil expect strong growth continu
next decad agil expect capit momentum recent
acquisit lasergan compani first clinic offer expect launch
util lasergen proprietari lightn termin technolog agil
current million busi workflow compon compani
believ clinic offer round offer raha ad clinic
like adopt mani lab experi technolog
could serv advantag agil access mani smaller lab
global due presenc patholog importantli compani also strong
biopharma relationship result companion diagnost partnership add
current workflow portfolio agil also releas magni autom
market nucleic acid therapeut size compound-annual-growth-rate raha
note number initi arena grow robustli activ
program end agil expertis oligo year current
second largest player space high barrier entri
hand oligo manufactur agil
second
manufactur site immedi increas manufactur capac
million opportun expans much progress
facil compani receiv temporari certif occup raha ad
agil excit numer partnership space
yet announc
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
